Phyton Biotech has successfully transferred the manufacturing process for the microbial production of Corallopyronin A (CorA). CorA is a novel anti-infective agent with the potential to address neglected tropical diseases. This achievement marks a significant step forward in the Company’s specialty GMP fermentation capabilities and supports the broader clinical development program led by the University Hospital Bonn (UKB), the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF).